Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GNFMC
ADC Name
LMB-7
Synonyms
B3 (Fv) PE 38; LMB 7; LMB-7; LMB7; NSC 658931
   Click to Show/Hide
Organization
National Cancer Institute
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Brain cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Murine mAb B3
  Antibody Info 
Antigen Name
Poly [ADP-ribose] polymerase 1 (PARP1)
  Antigen Info 
Payload Name
Pseudomonas exotoxin PE38
  Payload Info 
Therapeutic Target
Eukaryotic elongation factor 2 (EEF2)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random Cysteines
Puchem SID
381126861 , 509048 , 160682397 , 508550
ChEBI ID
CHEMBL2109307
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT00003020
Phase 1
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with leptomeningeal metastases.
Administration Dosage
.
Related Clinical Trial
NCT Number NCT00003020  Clinical Status Phase 1
Clinical Description Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
References
Ref 1 Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms